These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30117269)

  • 1. Triaryl Pyrazole Toll-Like Receptor Signaling Inhibitors: Structure-Activity Relationships Governing Pan- and Selective Signaling Inhibitors.
    Pollock JA; Sharma N; Ippagunta SK; Redecke V; Häcker H; Katzenellenbogen JA
    ChemMedChem; 2018 Oct; 13(20):2208-2216. PubMed ID: 30117269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Toll-like receptor signaling inhibitors based on selective activation of hierarchically acting signaling proteins.
    Ippagunta SK; Pollock JA; Sharma N; Lin W; Chen T; Tawaratsumida K; High AA; Min J; Chen Y; Guy RK; Redecke V; Katzenellenbogen JA; Häcker H
    Sci Signal; 2018 Aug; 11(543):. PubMed ID: 30108181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.
    Lin YC; Huang DY; Chu CL; Lin WW
    Mol Immunol; 2010 Apr; 47(7-8):1569-78. PubMed ID: 20138367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.
    Li TT; Ogino S; Qian ZR
    World J Gastroenterol; 2014 Dec; 20(47):17699-708. PubMed ID: 25548469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands.
    Arsenault RJ; Kogut MH; He H
    Cell Signal; 2013 Nov; 25(11):2246-54. PubMed ID: 23876795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of the TRIF-dependent signaling pathway of Toll-like receptors by luteolin.
    Lee JK; Kim SY; Kim YS; Lee WH; Hwang DH; Lee JY
    Biochem Pharmacol; 2009 Apr; 77(8):1391-400. PubMed ID: 19426678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting toll-like receptor signaling pathways for design of novel immune therapeutics.
    Hong-Geller E; Chaudhary A; Lauer S
    Curr Drug Discov Technol; 2008 Mar; 5(1):29-38. PubMed ID: 18537565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells.
    Tartey S; Takeuchi O
    Int Rev Immunol; 2017 Mar; 36(2):57-73. PubMed ID: 28060562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptors.
    Takeda K; Akira S
    Curr Protoc Immunol; 2015 Apr; 109():14.12.1-14.12.10. PubMed ID: 25845562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-Molecule Modulators of Toll-like Receptors.
    Wang Y; Zhang S; Li H; Wang H; Zhang T; Hutchinson MR; Yin H; Wang X
    Acc Chem Res; 2020 May; 53(5):1046-1055. PubMed ID: 32233400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family.
    Martin MU; Wesche H
    Biochim Biophys Acta; 2002 Nov; 1592(3):265-80. PubMed ID: 12421671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor signaling in parasitic infections.
    Ashour DS
    Expert Rev Clin Immunol; 2015 Jun; 11(6):771-80. PubMed ID: 25896399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quercetin regulates oxidized LDL induced inflammatory changes in human PBMCs by modulating the TLR-NF-κB signaling pathway.
    Bhaskar S; Shalini V; Helen A
    Immunobiology; 2011 Mar; 216(3):367-73. PubMed ID: 20828867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of protein-protein interactions in Toll-like receptor function.
    Berglund NA; Kargas V; Ortiz-Suarez ML; Bond PJ
    Prog Biophys Mol Biol; 2015 Oct; 119(1):72-83. PubMed ID: 26144017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycogen synthase kinase 3β in Toll-like receptor signaling.
    Ko R; Lee SY
    BMB Rep; 2016 Jun; 49(6):305-10. PubMed ID: 26996345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress in the development of Toll-like receptor (TLR) antagonists.
    Patra MC; Choi S
    Expert Opin Ther Pat; 2016 Jun; 26(6):719-30. PubMed ID: 27136061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptors (TLRs) and immune disorders.
    Akashi-Takamura S; Miyake K
    J Infect Chemother; 2006 Oct; 12(5):233-40. PubMed ID: 17109085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAGE and TLRs: relatives, friends or neighbours?
    Ibrahim ZA; Armour CL; Phipps S; Sukkar MB
    Mol Immunol; 2013 Dec; 56(4):739-44. PubMed ID: 23954397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of toll-like receptor and cytokine signaling--a unifying theme in ischemic tolerance.
    Karikó K; Weissman D; Welsh FA
    J Cereb Blood Flow Metab; 2004 Nov; 24(11):1288-304. PubMed ID: 15545925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense.
    Basith S; Manavalan B; Yoo TH; Kim SG; Choi S
    Arch Pharm Res; 2012 Aug; 35(8):1297-316. PubMed ID: 22941474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.